US-based Maxor Specialty Pharmacy, a VytlOne company, and a pharmacy solutions partner, announced on Wednesday that it has been selected by New Jersey-based biotech company Insmed to be a limited distribution provider of Brinsupri.
Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and paediatric patients 12 years of age and older.
The company said brinsupri is the latest addition to a growing number of limited distribution products available through VytlOne.
"We are excited to partner with Insmed for the launch of Brinsupri, the first FDA-approved medication for the treatment of bronchiectasis," said Joel Wright, president, VytlOne Pharmacy Services. "This milestone underscores our commitment to the rare disease community, and we are honoured to play a role in the improvement of the lives of our bronchiectasis patients."
Remegen's Telitacicept meets Sjogren's syndrome Phase III trial's primary endpoint
PainReform acquires majority stake in LayerBio to advance dropless cataract surgery therapy
Insmed's BRINSUPRI (brensocatib) non-cystic fibrosis bronchiectasis treatment approved by US FDA
Ocular Therapeutix secures FDA special protocol assessment for AXPAXLI NPDR trial
Novartis reports positive Phase III trial results for ianalumab in immune thrombocytopenia
Viatris' generic iron sucrose injection gains US FDA approval
NRx Pharmaceuticals secures FDA Fast Track designation for NRX-100 in treating suicidal depression
IO Biotech reports Phase 3 trial results for Cylembio plus pembrolizumab in advanced melanoma
Novartis reports positive Phase III results for ianalumab in Sjögren's disease